Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Nursing Clinical Insights Into the Benefits and Challenges of EGFR TKIs in the Treatment of NSCLC

Lung cancer is the leading cause of cancer death. Approximately 85% of lung cancer cases are non–small cell lung cancer (NSCLC), 10% to 15% of whic...

Available credits: 0.50


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Lung cancer is the leading cause of cancer death. Approximately 85% of lung cancer cases are non–small cell lung cancer (NSCLC), 10% to 15% of which are epidermal growth factor receptor (EGFR) mutation positive. The development of EGFR inhibitors (eg, tyrosine kinase inhibitors [TKIs]) has led to targeted therapy, advancing the management of NSCLC. Unfortunately, the disease often develops resistance to some of these therapies; however, significant progress has been made in the treatment of NSCLC. 

    Recent advances in next-generation EGFR TKIs have shown promising results in patients with EGFR mutation–positive refractory NSCLC.

    This activity provides learners with information regarding recent advances in the identification of predictive biomarkers and the EGFR TKI treatment paradigm, efficacy and safety information about approved and emerging TKIs used to treat EGFR mutation–positive NSCLC, and provides some insight into how healthcare clinicians can help educate patients and their caregivers about this topic. 

  • Learning Objectives

    • Discriminate among molecular characteristics or biomarkers that may be used to refine prognosis and/or predict response to an individual treatment in patients with non–small cell lung cancer
    • Demonstrate an understanding of personalized medicine based on molecular subtype of EGFR mutation–positive non–small cell lung cancer
    • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors in non–small cell lung cancer
    • Analyze data about the efficacy and safety of currently available and emerging EGFR tyrosine kinase inhibitors used to treat non–small cell lung cancer.
    • Identify best practices to facilitate oral therapy adherence among patients with non–small cell lung cancer
    • Recognize appropriate strategies for the management of toxicities from treatment with emerging drugs in EGFR mutation–positive advanced non–small cell lung cancer
  • Target Audience

    This activity is intended for oncology nurses, thoracic nurses, pulmonary nurses, and other healthcare professionals who treat and manage non–small cell lung cancer.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Lori McMullen, MSN, RN, OCN® has no real or apparent conflicts of interest to report.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; Jocelyn Timko,BS; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

  • Accreditation and Credit Designation Statements

    Accreditation Statement
    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

  • Terms of Use

    AXIS Contact Information
    For information about the accreditation of this activity, please contact AXIS at

    Fee Information
    There is no fee for this educational activity.

    Method of Participation and Request for Credit
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

  • Disclaimer

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Safeguards Against Commercial Bias
    AXIS Medical Education affirms that the content and format of the certified activity and its related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, AXIS employs several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for certified activities to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation guidelines, and resolution of any actual or perceived conflicts of interest that exist.

    We employ several metrics during review of content materials, including:

    1. Fair balance
      a. Recommendations must be based on a reasonable and valid interpretation of the information available on the subject matter
      b. No single product or service is overrepresented when other equal, competing products or services are available for inclusion
    2. Scientific objectivity of studies mentioned in the activity or used as the basis for content development
  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.